# To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

> **NCT06756269** · PHASE2 · RECRUITING · sponsor: **Shanghai Bovax Biotechnology Co., Ltd.** · enrollment: 330 (estimated)

## Conditions studied

- HPV Infection
- HPV-Related Carcinoma
- HPV-Related Intraepithelial Neoplasia
- Genital Wart

## Interventions

- **BIOLOGICAL:** Medium dose for 15-HPV vaccine
- **BIOLOGICAL:** High dose for 15-HPV vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** 9-HPV vaccine

## Key facts

- **NCT ID:** NCT06756269
- **Lead sponsor:** Shanghai Bovax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2025-10-30
- **Final completion:** 2026-01-13
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756269, "To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06756269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*